iRhythm Q3 2026: Revenue Rises, VitalConnect Joins the Band, and the Zio Rhythm Keeps Time
Overview: The numbers before the rhyme
iRhythm Holdings, Inc. (ticker: IRTC) reported its third quarter 2026 results, continuing a pattern you’d expect from a company that sells a wearable sensor with a fan club: revenue of $221.6 million, up 14.9% from the same period a year ago. The topline strength came with a gross margin of 74.2%, a sizable improvement of 310 basis points versus Q3 2025. The company also disclosed a GAAP net loss of $29.9 million, alongside an adjusted EBITDA of $51.2 million and an adjusted EBITDA margin of 23.1%—a margin expansion that makes the algebra look easy, even if the GAAP line isn’t.
On the liquidity and cash front, iRhythm reported unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026. Management lifted its revenue forecast for fiscal 2026 to a range of $890 million to $895 million and nudged the adjusted EBITDA margin target to 15.5%–16.0%. Translation: the band is playing louder, and the drummer doesn’t seem to be going off tempo.
The quarter also featured notable corporate housekeeping in the form of a major acquisition: VitalConnect closed on October 5, 2026, broadening iRhythm’s cardiac monitoring portfolio with an FDA-cleared mobile telemetry offering and signaling a more expansive “multi-vitals” strategy across the care continuum.
Operational Highlights: The beat goes on
- Zio Monitor drove volume-led revenue growth across cardiology, primary care, and international markets, underscoring demand for ambulatory cardiac monitoring.
- Margin expansion continued, supported by mix improvements and operational discipline.
- The VitalConnect acquisition added immediate capability and market reach, aligning with a broader multi-vitals playbook.
- Three large real-world studies published on Zio products—CAMELOT-ALERT, EXCALIBUR, and Zio Monitor performance versus Zio XT—demonstrated real-world advantages across more than 1.7 million patients.
- Regulatory and product expansion steps included FDA 510(k) submissions for pediatric use for Zio Monitor long-term monitoring.
- Strategic financing reinforced with a new $300 million senior secured revolving credit facility completed on November 3, 2026, adding liquidity for ongoing growth initiatives.
Leadership Commentary: A rhythm that invites more instruments
“Our third quarter results reflect the continued strength of our core business,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “Demand for Zio Monitor remains robust, with margin expansion and disciplined execution in our strategic priorities. With VitalConnect closed, we see early opportunities to broaden our capabilities across the ambulatory cardiac monitoring market and the continuum of care, including an immediate FDA-cleared mobile telemetry option.” The tone is pragmatic, not jubilant, and the portents are of a company intent on stacking capabilities rather than chasing fashion.
Metrics to watch: EPS, revenue forecast, and the earnings surprise question
The press release highlights GAAP net loss and a solid adjusted EBITDA figure, but it does not publish a standalone EPS figure in this excerpt. For investors tracking earnings per share (EPS) and its consensus, the absence of a stated EPS number means the usual calculation and the potential for any earnings surprise will hinge on future disclosures. In other words, if you care about EPS consensus, you’ll need the company’s next filing or conference call to see whether the under-the-hood numbers align with market expectations.
The company’s revenue forecast for 2026 is explicit, ranging from $890 million to $895 million, a signal that management believes growth can be sustained even as the company pivots toward a broader multi-vitals footprint. The combination of a raised revenue forecast and a double-click on adjusted EBITDA margin creates a narrative for both EPS trajectory and shareholder value, even if the current quarter’s GAAP loss muddies the water in the near term.
Strategic implications: What this might portend for IRTC and sector peers
If the VitalConnect integration unfolds as planned, iRhythm could accelerate cross-sell opportunities across its customer base and diversify revenue streams beyond the Zio Monitor’s core cadence. The real-world studies add a form of clinical validation that often translates into broader adoption and pricing power, but the path from registry to revenue is rarely a straight line; technology acquisitions carry integration risk and potential channel conflicts that even the most melodious quarter can’t fully mute.
For peers in the digital health and ambulatory monitoring space, the combination of a strong top line, improving gross margins, and a flexible capital structure (the revolving credit facility) signals a preference for growth with balance. The sector may start to reward steps that de-risk expansion—whether by deepening multi-vitals portfolios or by attaching FDA-cleared capabilities to existing platforms—more than pure point-product improvements.
Takeaways for investors and traders
- IRTC demonstrates healthy revenue momentum and margin improvement, even as the GAAP bottom line remains in the red.
- The VitalConnect acquisition broadens the company’s portfolio and may unlock cross-selling opportunities across Mayo Clinic-sized risk pools of patients who need mobile telemetry and beyond.
- The raised full-year revenue forecast and the addition of a sizable revolving credit facility reduce some near-term liquidity concerns while signaling confidence in longer-term growth.
- Investors watching EPS and earnings surprises will look to the next quarterly print or conference call for clarity on EPS consensus and the potential to flip from GAAP losses to earnings according to non-GAAP measures.
- Sector peers may take note: durable value creation may hinge on expanding the platform into multi-vitals ecosystems and communicating clear clinical and economic benefits to providers and payers.
Bottom line: A steady tempo with a larger orchestra on deck
iRhythm’s Q3 2026 results reinforce a theme that many health tech players would envy: revenue growth supported by a high gross margin, a disciplined cost and capital structure, and a strategic pivot toward broader monitoring capabilities through acquisitions. The real test will be how well VitalConnect integrates, how quickly the company can translate volume gains into sustained profitability, and whether the market’s ears are tuned to EPS expectations in the next report. For now, the rhythm suggests more instruments—Zio, VitalConnect, and perhaps one or two more instruments—may be joining the stage.